- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Nuklearmedizin, 58, 2, S. 150-
- Classification
-
Medizin, Gesundheit
- Event
-
Veröffentlichung
- (where)
-
Augsburg
- (who)
-
Universität Augsburg
- (when)
-
2019
- Event
-
Veröffentlichung
- (where)
-
Stuttgart
- (who)
-
Thieme
- (when)
-
2019
- Creator
-
Cytawa, W.
Bandurski, T.
Tran-Gia, J.
Schirbel, A.
Fukushima, K.
Wester, H. J.
Buck, A. K.
Lapa, Constantin Frederik Victor
- DOI
-
10.1055/s-0039-1683605
- URN
-
urn:nbn:de:bvb:384-opus4-629614
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:41 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cytawa, W.
- Bandurski, T.
- Tran-Gia, J.
- Schirbel, A.
- Fukushima, K.
- Wester, H. J.
- Buck, A. K.
- Lapa, Constantin Frederik Victor
- Universität Augsburg
- Thieme
Time of origin
- 2019
Other Objects (12)
68Ga-PSMA I&T PET/CT for primary staging of prostate cancer
68Ga-HBED-CC-PSMA PET/CT versus histopathology In primary localized prostate cancer: a voxel-wise comparison
Diagnostic performance of [18f]fluorocholine and [68ga]ga-psma pet/ct in prostate cancer: a comparative study
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens
Detection rate of 68Ga-PSMA Ligand PET/CT in patients with recurrent prostate cancer and androgen deprivation therapy
Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
DNA damage in blood leukocytes of prostate cancer patients undergoing PET/CT examinations with [68Ga]Ga-PSMA I&T
Comparison of tumor heterogeneity assessed with textural parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in patienst with metastatic prostate cancer
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
Stellenwert der 68Ga-PSMA-11 PET/CT bei Patienten mit bioptisch gesichertem Prostatakarzinom
Einfluss der 68Ga-HBED-CC PSMA PET/CT auf Diagnostik und Therapiemanagement des Prostatakarzinoms
Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference
68Ga-PSMA I&T PET/CT for primary staging of prostate cancer
68Ga-HBED-CC-PSMA PET/CT versus histopathology In primary localized prostate cancer: a voxel-wise comparison
Diagnostic performance of [18f]fluorocholine and [68ga]ga-psma pet/ct in prostate cancer: a comparative study
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens
Detection rate of 68Ga-PSMA Ligand PET/CT in patients with recurrent prostate cancer and androgen deprivation therapy
Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
DNA damage in blood leukocytes of prostate cancer patients undergoing PET/CT examinations with [68Ga]Ga-PSMA I&T
Comparison of tumor heterogeneity assessed with textural parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in patienst with metastatic prostate cancer
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
Stellenwert der 68Ga-PSMA-11 PET/CT bei Patienten mit bioptisch gesichertem Prostatakarzinom
Einfluss der 68Ga-HBED-CC PSMA PET/CT auf Diagnostik und Therapiemanagement des Prostatakarzinoms
Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference
68Ga-PSMA I&T PET/CT for primary staging of prostate cancer
68Ga-HBED-CC-PSMA PET/CT versus histopathology In primary localized prostate cancer: a voxel-wise comparison
Diagnostic performance of [18f]fluorocholine and [68ga]ga-psma pet/ct in prostate cancer: a comparative study
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens
Detection rate of 68Ga-PSMA Ligand PET/CT in patients with recurrent prostate cancer and androgen deprivation therapy
Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
DNA damage in blood leukocytes of prostate cancer patients undergoing PET/CT examinations with [68Ga]Ga-PSMA I&T
Comparison of tumor heterogeneity assessed with textural parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in patienst with metastatic prostate cancer
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
Stellenwert der 68Ga-PSMA-11 PET/CT bei Patienten mit bioptisch gesichertem Prostatakarzinom
Einfluss der 68Ga-HBED-CC PSMA PET/CT auf Diagnostik und Therapiemanagement des Prostatakarzinoms